Adipose-Derived Stem Cells Are More Potent Immunomodulators Than Those Derived from Bone Marrow
By LabMedica International staff writers Posted on 04 Jun 2013 |
A recent paper revealed that stem cells derived from fat (adipose) tissue were more potent than those originating from bone marrow as modulators of the body’s immune system.
Considering that adipose tissue-derived stem cells (AT-SCs) are far more plentiful in the body than those found in bone marrow (BM-MSCs), the findings reported by investigators at the Leiden University Medical Center (The Netherlands) should prompt further research into the use of AT-SCs in personalized immunomodulatory therapy.
The investigators compared the immunomodulatory capacities of BM-MSCs and AT-MSCs derived from age-matched donors. They reported in the May 21, 2013, online edition of the journal STEM CELLS Translational Medicine that BM-MSCs and AT-MSCs shared a similar immunophenotype and capacity for in vitro multilineage differentiation.
BM-MSCs and AT-MSCs showed comparable immunomodulatory effects as they were both able to suppress proliferation of stimulated peripheral blood mononuclear cells and to inhibit differentiation of monocyte-derived immature dendritic cells. However, at equal cell numbers, the AT-MSCs showed more potent immunomodulatory effects in both assays as compared with BM-MSCs. Moreover, AT-MSCs showed a higher level of secretion of cytokines that have been implicated in the immunomodulatory modes of action of multipotent stromal cells, such as interleukin-6 and transforming growth factor-beta-1 (TGF-beta-1).
AT-MSCs displayed higher metabolic activity than BM-MSCs, which meant that lower numbers of AT-MSCs could evoke the same level of immunomodulation as higher numbers of BM-MSCs.
Considering that adipose tissue-derived stem cells (AT-SCs) are far more plentiful in the body than those found in bone marrow (BM-MSCs), the findings reported by investigators at the Leiden University Medical Center (The Netherlands) should prompt further research into the use of AT-SCs in personalized immunomodulatory therapy.
The investigators compared the immunomodulatory capacities of BM-MSCs and AT-MSCs derived from age-matched donors. They reported in the May 21, 2013, online edition of the journal STEM CELLS Translational Medicine that BM-MSCs and AT-MSCs shared a similar immunophenotype and capacity for in vitro multilineage differentiation.
BM-MSCs and AT-MSCs showed comparable immunomodulatory effects as they were both able to suppress proliferation of stimulated peripheral blood mononuclear cells and to inhibit differentiation of monocyte-derived immature dendritic cells. However, at equal cell numbers, the AT-MSCs showed more potent immunomodulatory effects in both assays as compared with BM-MSCs. Moreover, AT-MSCs showed a higher level of secretion of cytokines that have been implicated in the immunomodulatory modes of action of multipotent stromal cells, such as interleukin-6 and transforming growth factor-beta-1 (TGF-beta-1).
AT-MSCs displayed higher metabolic activity than BM-MSCs, which meant that lower numbers of AT-MSCs could evoke the same level of immunomodulation as higher numbers of BM-MSCs.
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples